GlassScriptPhysician profile
Perri Clifford
NPI 1285246488
$7,091.86
in general payments reported to CMS, 2019-2025
45 companies · $1,645 in 2025
The $1,645 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $699 · 2022: $1,039 · 2023: $1,949 · 2024: $1,759 · 2025: $1,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,353.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,307.82 | 2021-2025 | |
| Pfizer INC. | $693.46 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $685.77 | 2022-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $604.54 | 2022-2025 | Vyepti, Rexulti |
| Ucb, INC. | $502.08 | 2021-2025 | Nayzilam, Zilbrysq, Briviact |
| Novartis Pharmaceuticals Corporation | $358.68 | 2021-2025 | |
| Sk Life Science, INC. | $298.74 | 2021-2025 | Xcopri |
| Lilly USA, LLC | $279.74 | 2021-2024 | Emgality, Reyvow, Amyvid |
| Biogen, INC. | $240.98 | 2021-2024 | Tysabri, Vumerity, Avonex |
| Teva Pharmaceuticals USA, INC. | $184.27 | 2021-2025 | Austedo Xr, Austedo Xr |
| Emd Serono, INC. | $138.86 | 2022-2024 | Mavenclad |
| Amgen INC. | $134.90 | 2021-2023 | Aimovig |
| Argenx US, INC. | $116.62 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Mdd US Operations, LLC | $111.63 | 2021-2024 | Gocovri, Gocovri, Apokyn |
| Sunovion Pharmaceuticals INC. | $110.66 | 2021-2022 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $95.48 | 2021-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Xeris Pharmaceuticals, INC. | $89.93 | 2023-2025 | Keveyis, Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $87.00 | 2023-2024 | Aptiom |
| Amneal Pharmaceuticals LLC | $76.07 | 2024 | Crexont, Rytary |
| Neurelis, INC. | $69.51 | 2022 | |
| Impel Pharmaceuticals INC. | $67.81 | 2022-2023 | Trudhesa |
| Eisai INC. | $65.77 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $61.09 | 2022 | |
| Cala Health, INC. | $54.88 | 2024-2025 | Cala Kiq, Cala Kiq, Cala Trio |
| Noctrix Health, INC. | $53.62 | 2025 | Nidra |
| Alexion Pharmaceuticals, INC. | $52.31 | 2023-2024 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $50.53 | 2024-2025 | Rexulti |
| Celgene Corporation | $47.97 | 2021-2024 | Zeposia |
| Vertex Pharmaceuticals Incorporated | $44.17 | 2025 | |
| Genentech USA, INC. | $40.56 | 2023-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Janssen Biotech, INC. | $37.74 | 2025 | |
| Allergan, INC. | $33.41 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $31.21 | 2021-2025 | Onzetra Xsail |
| Tg Therapeutics, INC. | $28.50 | 2025 | |
| Abbott Laboratories | $26.65 | 2023 | Amplatzer Talisman |
| Merz Pharmaceuticals, LLC | $24.94 | 2025 | Xeomin |
| Boston Scientific Corporation | $24.55 | 2023 | Watchman Access System |
| Genzyme Corporation | $24.49 | 2022 | |
| Avanir Pharmaceuticals, INC. | $21.74 | 2022 | |
| Cycle Pharmaceuticals INC | $20.82 | 2025 | Bafiertam, Tascenso Odt |
| Vanda Pharmaceuticals INC. | $20.34 | 2025 | Ponvory |
| E.R. Squibb & Sons, L.L.C. | $18.94 | 2021 | |
| Greenwich Biosciences, INC. | $18.47 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.35 | 2023 | Evusheld |
| Catalyst Pharmaceuticals, INC. | $16.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perri Clifford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.